REV-MED (CEO: Edward BG Shin) has officially announced its entry into the consulting market for Advanced Regenerative Medicine Practice Institutions, aiming to provide healthcare organizations with practical guidance based on more than 15 years of experience in regenerative medicine and cell-processing technologies.
As a company recognized for developing the NovaStem platform and other regenerative medicine solutions, REV-MED stated that the new consulting service is designed to transfer its accumulated clinical and research expertise directly to medical institutions preparing to enter the advanced regenerative medicine field.
According to the company, successful designation as an Advanced Regenerative Medicine Practice Institution requires a balanced integration of three essential components: facilities, equipment, and personnel. While many consulting providers focus primarily on infrastructure development, REV-MED believes that long-term success depends equally on research capability and operational readiness.
A company representative explained:
“Many institutions invest heavily in facility construction and equipment procurement. However, after designation, they often face significant challenges when developing clinical research programs and treatment plans. Infrastructure alone is not enough.”
REV-MED emphasized that its consulting model is built around a research-centered approach. The program focuses on helping institutions establish systems that address safety considerations associated with cell processing and regenerative medicine activities while also preparing specialized personnel for clinical and research operations.
The company’s services include support for:
- Research-focused institutional planning
- Safety management systems for regenerative medicine operations
- Training programs for research nurses and cell-processing personnel
- Clinical research protocol development
- Operational preparation for regenerative medicine programs
- Long-term academic and technical support
REV-MED noted that these services are based on practical experience gained through years of collaboration with researchers, clinicians, and regenerative medicine specialists.
Commenting on the initiative, CEO Edward BG Shin stated:
“Cell-based regenerative medicine requires sophisticated scientific expertise because it involves working with living biological materials. Just as NovaStem has demonstrated technological excellence, we hope this consulting service will contribute to elevating the overall quality of regenerative medicine institutions throughout Korea.”
He added:
“Many hospitals invest heavily in infrastructure, but often lack the software—the research strategy, clinical planning, and operational expertise needed to translate those investments into successful clinical programs. REV-MED aims to become the partner that fills that gap. Our ultimate goal is not simply to help institutions obtain designation, but to contribute to Korea’s emergence as a global hub for regenerative medicine.”
Through this initiative, REV-MED seeks to strengthen the research capabilities of healthcare institutions while supporting the continued growth of Korea’s regenerative medicine ecosystem.
Source: Hemophilia Life
REV-MED (CEO: Edward BG Shin) has officially announced its entry into the consulting market for Advanced Regenerative Medicine Practice Institutions, aiming to provide healthcare organizations with practical guidance based on more than 15 years of experience in regenerative medicine and cell-processing technologies.
As a company recognized for developing the NovaStem platform and other regenerative medicine solutions, REV-MED stated that the new consulting service is designed to transfer its accumulated clinical and research expertise directly to medical institutions preparing to enter the advanced regenerative medicine field.
According to the company, successful designation as an Advanced Regenerative Medicine Practice Institution requires a balanced integration of three essential components: facilities, equipment, and personnel. While many consulting providers focus primarily on infrastructure development, REV-MED believes that long-term success depends equally on research capability and operational readiness.
A company representative explained:
“Many institutions invest heavily in facility construction and equipment procurement. However, after designation, they often face significant challenges when developing clinical research programs and treatment plans. Infrastructure alone is not enough.”
REV-MED emphasized that its consulting model is built around a research-centered approach. The program focuses on helping institutions establish systems that address safety considerations associated with cell processing and regenerative medicine activities while also preparing specialized personnel for clinical and research operations.
The company’s services include support for:
REV-MED noted that these services are based on practical experience gained through years of collaboration with researchers, clinicians, and regenerative medicine specialists.
Commenting on the initiative, CEO Edward BG Shin stated:
“Cell-based regenerative medicine requires sophisticated scientific expertise because it involves working with living biological materials. Just as NovaStem has demonstrated technological excellence, we hope this consulting service will contribute to elevating the overall quality of regenerative medicine institutions throughout Korea.”
He added:
“Many hospitals invest heavily in infrastructure, but often lack the software—the research strategy, clinical planning, and operational expertise needed to translate those investments into successful clinical programs. REV-MED aims to become the partner that fills that gap. Our ultimate goal is not simply to help institutions obtain designation, but to contribute to Korea’s emergence as a global hub for regenerative medicine.”
Through this initiative, REV-MED seeks to strengthen the research capabilities of healthcare institutions while supporting the continued growth of Korea’s regenerative medicine ecosystem.
Source: Hemophilia Life